BACKGROUND: High-density lipoprotein (HDL) protects the artery wall by removing cholesterol from lipid-laden macrophages. However, recent evidence suggests that HDL might also inhibit atherogenesis by combating inflammation. METHODS AND RESULTS: To identify potential antiinflammatory mechanisms, we challenged macrophages with lipopolysaccharide, an inflammatory microbial ligand for Toll-like receptor 4. HDL inhibited the expression of 30 (277 of 911) of the genes normally induced by lipopolysaccharide, microarray analysis revealed. One of its major targets was the type I interferon response pathway, a family of potent viral immunoregulators controlled by Toll-like receptor 4 and the TRAM/TRIF signaling pathway. Unexpectedly, the ability of HDL to inhibit gene expression was independent of macrophage cholesterol stores. Immunofluorescent studies suggested that HDL promoted TRAM translocation to intracellular compartments, which impaired subsequent signaling by Toll-like receptor 4 and TRIF. To examine the potential in vivo relevance of the pathway, we used mice deficient in apolipoprotein A-I, the major protein of HDL. After infection with Salmonella typhimurium, a Gram-negative bacterium that expresses lipopolysaccharide, apolipoprotein A-I-deficient mice had 6-fold higher plasma levels of interferon-β, a key regulator of the type I interferon response, than did wild-type mice. CONCLUSIONS: HDL inhibits a subset of lipopolysaccharide-stimulated macrophage genes that regulate the type I interferon response, and its action is independent of sterol metabolism. These findings raise the possibility that regulation of macrophage genes by HDL might link innate immunity and cardioprotection.
BACKGROUND: High-density lipoprotein (HDL) protects the artery wall by removing cholesterol from lipid-laden macrophages. However, recent evidence suggests that HDL might also inhibit atherogenesis by combating inflammation. METHODS AND RESULTS: To identify potential antiinflammatory mechanisms, we challenged macrophages with lipopolysaccharide, an inflammatory microbial ligand for Toll-like receptor 4. HDL inhibited the expression of 30 (277 of 911) of the genes normally induced by lipopolysaccharide, microarray analysis revealed. One of its major targets was the type I interferon response pathway, a family of potent viral immunoregulators controlled by Toll-like receptor 4 and the TRAM/TRIF signaling pathway. Unexpectedly, the ability of HDL to inhibit gene expression was independent of macrophage cholesterol stores. Immunofluorescent studies suggested that HDL promoted TRAM translocation to intracellular compartments, which impaired subsequent signaling by Toll-like receptor 4 and TRIF. To examine the potential in vivo relevance of the pathway, we used mice deficient in apolipoprotein A-I, the major protein of HDL. After infection with Salmonella typhimurium, a Gram-negative bacterium that expresses lipopolysaccharide, apolipoprotein A-I-deficient mice had 6-fold higher plasma levels of interferon-β, a key regulator of the type I interferon response, than did wild-type mice. CONCLUSIONS: HDL inhibits a subset of lipopolysaccharide-stimulated macrophage genes that regulate the type I interferon response, and its action is independent of sterol metabolism. These findings raise the possibility that regulation of macrophage genes by HDL might link innate immunity and cardioprotection.
Authors: Mohamad Navab; Gattadahalli M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Benjamin J Ansell; Alan M Fogelman Journal: Nat Clin Pract Endocrinol Metab Date: 2006-09
Authors: Brian J Van Lenten; Alan C Wagner; Mohamad Navab; G M Anantharamaiah; Eric Ka-Wai Hui; Debi P Nayak; Alan M Fogelman Journal: Circulation Date: 2004-11-08 Impact factor: 29.690
Authors: A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler Journal: Science Date: 1998-12-11 Impact factor: 47.728
Authors: Andrew J Murphy; Kevin J Woollard; Anh Hoang; Nigora Mukhamedova; Roslynn A Stirzaker; Sally P A McCormick; Alan T Remaley; Dmitri Sviridov; Jaye Chin-Dusting Journal: Arterioscler Thromb Vasc Biol Date: 2008-07-10 Impact factor: 8.311
Authors: Thomas A Halsey; Andrés Vazquez-Torres; Daniel J Gravdahl; Ferric C Fang; Stephen J Libby Journal: Infect Immun Date: 2004-02 Impact factor: 3.441
Authors: Lijian Wang; Lynne Harrington; Estela Trebicka; Hai Ning Shi; Jonathan C Kagan; Charles C Hong; Herbert Y Lin; Jodie L Babitt; Bobby J Cherayil Journal: J Clin Invest Date: 2009-10-05 Impact factor: 14.808
Authors: Timothy J Sontag; Ronald Carnemolla; Tomas Vaisar; Catherine A Reardon; Godfrey S Getz Journal: J Lipid Res Date: 2012-03-08 Impact factor: 5.922
Authors: Thomas Weichhart; Chantal Kopecky; Markus Kubicek; Michael Haidinger; Dominik Döller; Karl Katholnig; Cacang Suarna; Philipp Eller; Markus Tölle; Christopher Gerner; Gerhard J Zlabinger; Markus van der Giet; Walter H Hörl; Roland Stocker; Marcus D Säemann Journal: J Am Soc Nephrol Date: 2012-01-26 Impact factor: 10.121
Authors: Katya B Rubinow; Chongren Tang; Andrew N Hoofnagle; Christin N Snyder; John K Amory; Jay W Heinecke; Stephanie T Page Journal: Steroids Date: 2012-01-15 Impact factor: 2.668
Authors: Ling Guo; Zhong Zheng; Junting Ai; Deborah A Howatt; Paul R Mittelstadt; Seth Thacker; Alan Daugherty; Jonathan D Ashwell; Alan T Remaley; Xiang-An Li Journal: Arterioscler Thromb Vasc Biol Date: 2014-03-06 Impact factor: 8.311
Authors: Edward A Fisher; Jonathan E Feig; Bernd Hewing; Stanley L Hazen; Jonathan D Smith Journal: Arterioscler Thromb Vasc Biol Date: 2012-12 Impact factor: 8.311
Authors: Anuradha Vivekanandan-Giri; Jessica L Slocum; Jaeman Byun; Chongren Tang; Robin L Sands; Brenda W Gillespie; Jay W Heinecke; Rajiv Saran; Mariana J Kaplan; Subramaniam Pennathur Journal: Ann Rheum Dis Date: 2013-01-12 Impact factor: 19.103